Increased Risk of Myocardial Infarction in Inclusion Body Myositis: A Non-Concurrent Cohort Study

Area of Science:

• Cardiology
• Neurology
• Rheumatology

Background:

• Idiopathic inflammatory myopathies, excluding inclusion body myositis (IBM), are linked to adverse cardiovascular outcomes like myocardial infarction (MI).
• This study specifically investigates the cardiovascular disease risk within the IBM patient cohort.

Purpose of the Study:

• To evaluate the risk of cardiovascular disease (CVD) in patients diagnosed with inclusion body myositis (IBM).

Main Methods:

• A non-concurrent cohort study used the Rochester Epidemiologic Project, matching 50 IBM patients with 294 controls.
• Cardiovascular risk factors were assessed, and inverse probability of treatment weighting adjusted for baseline covariates.
• Follow-up determined relative risks (RR) and hazard ratios (HR) for MI, ischemic stroke, cardiomyopathy, congestive heart failure (CHF), and peripheral vascular disease (PVD).

Main Results:

• Patients with IBM showed a significantly increased hazard of MI (HR: 5.79) compared to matched referents.
• A higher prevalence of pre-existing peripheral vascular disease (PVD) was noted in the IBM cohort.
• No increased risk was found for ischemic stroke, cardiomyopathy, or CHF in IBM patients.

Conclusions:

• Inclusion body myositis (IBM) is associated with a substantially elevated risk of myocardial infarction (MI).
• There is a need for intensified cardiovascular surveillance and proactive prevention strategies in the management of IBM patients.